Journal of Pediatric Neurology 2004; 02(04): 205-211
DOI: 10.1055/s-0035-1557221
Original Article
Georg Thieme Verlag KG Stuttgart – New York

Hereditary neuropathies with self-mutilation

Natan Gadoth
1   Department of Neurology, Meir General Hospital, Kfar Saba, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
,
Eliyah Mass
2   Department of Pediatric Dentistry, Goldschleger School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel
› Author Affiliations

Subject Editor:
Further Information

Publication History

01 April 2004

22 May 2004

Publication Date:
29 July 2015 (online)

Abstract

Although self-mutilation (SM) is not rare in the general population, the most common causes for this mode of destructive behavior are mental retardation and psychiatric ailments. There are 2 types of neuropathies with mutilation, those with spontaneous mutilation of tissues and the others in which the patients mutilate themselves. A number of hereditary disorders are associated with SM. Among the eight MIM (Mendelian Inheritance in Man) entries associated with SM, there are four conditions, which are associated with peripheral neuropathy (choreo-acanthocytosis,.acanthocytosis with neurological impairment, congenital insensitivity to pain with anhydrosis and the paroxysmal neuropathy of type I tyrosinemia). The other four (Tourette syndrome, Lesch-Nyhan syndrome, Lesch-Nyhan phenotype with normal hypoxanthine guanine phosphoribosyle transferase and Cri-du-chat syndrome) are not associated with peripheral neuropathy. It is quite surprising that in the latest editions of the classical textbooks of pediatrics, pediatric neurology and adult neurology SM is mentioned only with regard to Lesch-Nyhan syndrome. In this paper, we describe our experience with a number of hereditary mutilating neuropathies and review some of the recent advances in the neurobiology of SM. The recognition and awareness of this outstanding clinical sign may be helpful in reaching a correct diagnosis and offering symptomatic treatment, to avoid potential tissue damage at an earlier stage of the disease. (J Pediatr Neurol 2004; 2(4): 205–211).